Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Clinical evidence

VTS301 parts A and B

69 evidence topics · 18 sources

Objective
Location and study date
Registry study dates and enrollment
FieldQuoted record
Study start (actual)“2015-10”
Primary completion (actual)“2018-03-28”
Study completion (actual)“2018-03-28”
Enrollment (actual)“56”
Results first posted“2023-02-22”
Study sites by country
CountryFacility
United States“University of Alabama at Birmingham”
United States“Children's Hospital of Orange County”
United States“University of California San Francisco”
United States“University of Colorado Denver”
United States“Shands Children's Hospital”
United States“Rush University Medical Center”
United States“Eunice Kennedy Shriver National Institute of Child Health and Human Development”
United States“Boston Children's Hospital”
United States“Montefiore Medical Center”
United States“University of North Carolina”
United States“Lehigh Valley Health Network”
United States“The Children's Hospital of Philadelphia”
United States“Dell Children's Medical Center of Central Texas”
United States“Multicare Institute for Research and Innovation”
Australia“The Prince of Wales Hospital”
Australia“Monash Medical Centre”
Australia“Royal Melbourne Hospital”
Australia“Royal Perth Hospital”
France“CHU Paris Est - Hospital d'Enfants Armand-Trousseau”
Germany“Katholisches Klinikim Bochum gGmbH”
Germany“Universitaetsklinikum Mainz”
Germany“Universitaetsklinikum Muenster”
New Zealand“Waikato Hospital”
Singapore“National University Hospital (Singapore) Pte, Ltd”
Spain“Hospital Universitario del Valle Hebron”
Turkey“Hacettepe University Medical Faculty”
Turkey“Gazi University Medical Faculty”
United Kingdom“Great Ormond Street Hospital”
United Kingdom“Birmingham Women's and Children's NHS Trust”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using the 4-Item NPC severity scale composite score as a co-primary endpoint
Inter-rater reliability of central NPC-SS scoring in this trial

“The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the co-primary endpoints
AnalysisSham controlAdrabetadex
4-item NPC-SS composite, participants analyzed“18”“38”
Participants analyzed for secondary endpoints
Outcome measureSham controlAdrabetadex
NPC-SS total score excluding hearing and ABR“18”“37”
Annualized rate of change (slope) of NPC-SS composite“14”“34”
Description of analysis sets
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
MilestonePart A adrabetadex 900 mgPart A adrabetadex 1200 mgPart A adrabetadex 1800 mgPart A shamPart B adrabetadex 900 mgPart B sham
Started“3”“3”“3”“3”“29”“15”
Completed“3”“3”“3”“3”“27”“14”
Not completed“0”“0”“0”“0”“2”“1”
Withdrawal by subject“0”“0”“0”“0”“2”“1”
Baseline characteristics
Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record
CharacteristicSham control (n = 18)Adrabetadex (n = 38)Total (n = 56)
Age, years, mean (SD)“11.7(5.10)”“12.7(5.64)”“12.4(5.45)”
Female“10”“16”“26”
Male“8”“22”“30”
White“16”“31”“47”
Asian“1”“4”“5”
Hispanic or Latino“3”“3”“6”
Baseline 4-item NPC-SS composite score
StatisticSham controlAdrabetadex
Baseline mean“8.1”“8.8”
Baseline standard deviation“4.27”“3.12”
Baseline weight, miglustat use, seizures, symptom duration, and total severity score
CharacteristicAdrabetadex (N=38)Sham control (N=18)
Weight (kg), mean (SD)“48.1 (25.27)”“40.2 (18.98)”
Miglustat use, n (%)“25 (66)”“9 (50)”
Seizures, n (%)“15 (39)”“5 (28)”
Duration of neurologic symptoms (years), mean (SD)“7.1 (4.15)”“5.9 (5.16)”
Baseline NPC-CSS total score (minus hearing/ABR), mean (SD)“17.8 (6.48)”“16.9 (8.16)”
Efficacy results
Co-primary endpoint: change in 4-item NPC-SS composite score at Week 52
StatisticSham control (n = 18)Adrabetadex (n = 38)
Change from baseline at Week 52, mean“-0.1”“0.0”
Change from baseline at Week 52, standard deviation“1.55”“2.45”
Co-primary endpoint: clinician CGIC at Week 52
CGIC categorySham control (n = 18)Adrabetadex (n = 38)
Markedly improved (1)“0”“0”
Moderately improved (2)“1”“5”
Minimally improved (3)“4”“9”
Unchanged (4)“9”“16”
Minimally worse (5)“2”“6”
Moderately worse (6)“2”“1”
Markedly worse (7)“0”“1”
Secondary endpoints reported in the ClinicalTrials.gov results
Outcome measureSham controlAdrabetadex
NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD)“-0.74(2.357)”“-0.34(4.226)”
Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants“13”“22”
Participants who qualified for the rescue option“2”“2”
Time to one-point worsening in NPC-SS composite score, median days (95% CI)“118 (55 to 364)”“169 (70 to 278)”
9-Hole Peg Test, change at Week 52, seconds, mean (SD)“-1.49(15.958)”“-1.79(34.760)”
Annualized rate of change (slope) of NPC-SS composite, mean (SD)“-0.05(1.640)”“0.08(2.441)”
Timed Up and Go test and total NPC-SS including hearing
Outcome measureSham controlAdrabetadex
Timed Up and Go, change at Week 52, seconds, mean“0.86”“2.70”
Timed Up and Go, change at Week 52, seconds, SD“19.232”“9.633”
Total NPC-SS with hearing and ABR, change at Week 52, mean“0.000”“0.75”
Total NPC-SS with hearing and ABR, change at Week 52, SD“1.000”“4.500”
Change in each NPC-SS domain at Week 52
Domain, change from baseline at Week 52Sham control, meanSham control, SDAdrabetadex, meanAdrabetadex, SD
Ambulation“0.00”“0.679”“0.06”“1.434”
Fine motor“0.07”“0.917”“0.24”“1.103”
Cognition“-0.14”“0.663”“0.06”“0.919”
Swallowing“0.00”“1.109”“-0.29”“1.360”
Memory“0.00”“0.784”“0.18”“1.218”
Speech“0.14”“0.663”“-0.18”“0.673”
Eye movement“0.00”“0.679”“-0.06”“0.547”
Hearing“-0.22”“1.302”“1.14”“1.236”
Seizures“-0.50”“1.286”“-0.06”“0.952”
Health-related quality of life and patient-reported outcomes
EQ-5D-3L visual analog scale at baseline and Week 52
Time pointSham control meanSham control SDAdrabetadex meanAdrabetadex SD
Baseline“71.9”“16.28”“68.3”“19.97”
Week 52“73.2”“13.04”“75.7”“19.00”
Safety results
Deaths, serious adverse events, and other adverse events by arm
EventPart A adrabetadex 900 mgPart A adrabetadex 1200 mgPart A adrabetadex 1800 mgPart A shamPart B adrabetadex 900 mgPart B sham
All-cause mortality“0/3 (0.00%)”“0/3 (0.00%)”“1/3 (33.33%)”“0/3 (0.00%)”“0/29 (0.00%)”“1/15 (6.67%)”
Any serious adverse event“1/3 (33.33%)”“0/3 (0.00%)”“2/3 (66.67%)”“0/3 (0.00%)”“16/29 (55.17%)”“3/15 (20.00%)”
Any other (non-serious) adverse event“3/3 (100.00%)”“3/3 (100.00%)”“3/3 (100.00%)”“3/3 (100.00%)”“28/29 (96.55%)”“14/15 (93.33%)”
Serious adverse events of hearing, seizure, and aspiration in Part B
Serious adverse eventPart B adrabetadex 900 mgPart B sham
Deafness“3/29 (10.34%)”“0/15 (0.00%)”
Hearing impaired“3/29 (10.34%)”“1/15 (6.67%)”
Seizure“3/29 (10.34%)”“1/15 (6.67%)”
Aspiration“2/29 (6.90%)”“1/15 (6.67%)”
Pneumonia aspiration“3/29 (10.34%)”“0/15 (0.00%)”
Study limitations
Summary: design limitations of Parts A and B
  • Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
  • Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
  • Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
  • Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
  • Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
  • Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
  • Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
  • Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
  • Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.